Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).

Dante PennipedeGhulam Rehman MohyuddinRyan HawkinsSiddhartha GangulyLeyla ShuneNausheen AhmedMeera MohanWei CuiZahra MahmoudjafariJoseph McGuirkShebli AtrashAl-Ola Abdallah

Published in: European journal of haematology (2021)

KCd showed clinically meaningful efficacy and manageable safety profile in patients with triple-class RRMM in real-world.

Keyphrases

multiple myeloma
high dose
low dose
acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
replacement therapy